At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 51 enrolled
Drug / intervention
Travoprost 0.004% ophthalmic solution (TRAVATAN) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients
In Brief
A Phase 4 clinical trial evaluating Travoprost 0.004% ophthalmic solution (TRAVATAN) and Tafluprost 0.0015% ophthalmic solution for Glaucoma. Completed, enrolled 51 participants.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionMar 2010
TodayJul 2026
First PostedAug 27, 2009
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.8 years ago
Interventions
Travoprost 0.004% ophthalmic solution (TRAVATAN)drug
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Tafluprost 0.0015% ophthalmic solutiondrug
One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration